Israeli startup Kadimastem to merge With NLS Pharmaceutics

ANI

Updated At : 03:11 PM Feb 02, 2025 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

Tel Aviv [Israel], February 2 (ANI/TPS): Shareholders of the Israeli bio-pharmaceutical startup, Kadimastem Ltd. approved the company's merger with the Swiss bio-pharmaceutical company NLS Limited on Thursday.

Founded in 2009 and based in Ness Ziona, Kadmimastem is a clinical-stage cell therapy company, developing "off-the-shelf," allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells.

The Zurich-based NLS focuses on the discovery and development of innovative therapies for rare and complex central nervous system disorders. Its shareholders are due to meet to approve the merger. (ANI/TPS)

(The story has come from a syndicated feed and has not been edited by the Tribune Staff.)

Tags :

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles